MannKind Corp - Company Profile
Powered by 
All the data and insights you need on MannKind Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date MannKind Corp Strategy Report
- Understand MannKind Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
MannKind Corp Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of MannKind Corp Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 18 Jul 2022 | Lorem |
| United’s Tyvaso Phase II/III PH-ILD study nears accrual with quick enrollment, source says | 23 May 2019 | Manasi Vaidya |
| Liquidia and Mannkind’s dry powder inhaler pursuits for PAH generate high physician appeal to replace United’s Tyvaso and other oral prostacyclins, experts say | 31 Jan 2019 | Manasi Vaidya |
| Oramed’s oral insulin has dubious T1D prospects after dissimilar past study designs; oral advantage deliberated – experts | 21 Sep 2016 | Alexandra Thompson |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer